Clinical Trials in Yunnan, China
1 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 2
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
Non-small Cell Lung Cancer
RemeGen Co., Ltd.80 enrolled34 locationsNCT06962865
Recruiting
Phase 1Phase 2
Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments
Ovarian CancerPancreatic CarcinomaAdvanced Solid Tumors+1 more
Evopoint Biosciences Inc.200 enrolled24 locationsNCT06799637